Immuno-Biological Laboratories Co., Ltd. (4570) Cash flow
Market cap
¥8.9B
P/E ratio
25.7x
Develops antibody-based diagnostic tools and testing services for medical research, plus manufactures cosmetics using human-type collagen from silkworms.
| 2015/03 | 2016/03 | 2017/03 | 2018/03 | 2019/03 | 2020/03 | 2021/03 | 2022/03 | 2023/03 | 2024/03 | 2025/03 | 2026/03 | |
| Depreciation & amortization | 96 | 75 | 183 | - | - | - | - | - | - | 2 | 15 | 19 |
| Cash from operations | -109 | -17 | -56 | 74 | -244 | -609 | -194 | -93 | 26 | 134 | 183 | 301 |
| Capital expenditures | -57 | -695 | -399 | -1 | - | - | -13 | - | - | -16 | -60 | -33 |
| Cash from investing | 22 | -608 | -458 | -6 | -593 | 11 | -17 | -156 | 30 | -24 | -54 | -116 |
| Payments for dividends | -0 | -0 | -0 | - | - | - | - | - | - | - | - | - |
| Proceeds from issuance of term debt, net | 400 | - | 330 | - | 30 | - | 50 | 60 | - | 10 | 20 | - |
| Repayments of term debt | -138 | -102 | -138 | -146 | -164 | -109 | -66 | -21 | -4 | -14 | -52 | -29 |
| Cash from financing | 164 | 287 | 2,146 | -138 | -126 | 81 | -216 | 144 | 1 | 1 | -32 | -27 |